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ABSTRACT 
It is recognised that patients may become sensitized to donor-specific HLA antigens 
as a result of previous antigenic exposures, classically through previous 
transplantation, pregnancy or blood transfusion. We present an unusual case of a 
patient who unexpectedly developed a range of anti-HLA antibodies following 
orthopaedic surgery where a bone graft was deployed intraoperatively. 
 
We describe the case of a 52-year-old male awaiting a renal transplantation, 
undergoing elective orthopaedic surgery requiring a small volume bone graft. His 
post operative antibody profile was found to be substantially changed compared to 
his previous negative samples, with the presence of HLA-DR, DQ and DP 
specificities, at levels that would be likely to give a positive flow cytometry 
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crossmatch and therefore according to local procedures required listing as 
unacceptable antigens for organ allocation. We perform a literature review of all 
previous cases of allosensitization following bone graft. 
This case is the first to demonstrate allosensitization following minor surgery with low 
volume bone graft. Previous evidence is very limited and pertains only to massive 
osteochondral surgery for trauma or malignancy, and is confounded by potential 
concomitant blood transfusion. Clinicians should be aware of the risk of 
allosensitization where bone grafts are used. 
 
Introduction 
It is well recognised that patients may become sensitized to donor-specific HLA 
antigens as a result of previous antigenic exposures, classically through previous 
transplantation, pregnancy or blood transfusion. The development of anti HLA 
antibodies has important implications for subsequent time spent on transplant 
waiting lists as highly sensitized patients are more difficult to match with a donor 
organ. Furthermore, the presence of anti-HLA antibodies at the time of transplant , 
particularly donor specific antibodies (DSA), is correlated with poorer long term renal 
transplant survival.(1,2) 
In the United States 20,000 patients awaiting a renal transplant are considered 
highly sensitized and these patients subsequently spend longer on the waiting list 
than those without donor specific antibodies.(3,4) These highly sensitized patients 
constitute approximately 10% of all active deceased renal transplants recorded in the 
UNOS registry.(5) 
A
cc
ep
te
d 
A
rt
ic
le
This article is protected by copyright. All rights reserved. 
Thus, minimisation of the development of anti-HLA antibodies is of vital importance 
to potential transplant recipients and clinical practice should attempt to mitigate these 
risks wherever possible. 
Bone grafts are traditionally thought to represent a low immunological risk of 
alloimmunization, perhaps due to uncertainty surrounding viability of remaining 
marrow and antigen presenting cells in graft material. However, there is a small body 
of evidence beginning to accumulate which suggests a previously unrecognised risk 
is associated with bone grafts, which may be clinically important for some 
patients.(6) We present an unusual case of a patient who unexpectedly developed a 
broad range of anti-HLA antibodies following orthopaedic surgery where a bone graft 
was deployed as part of the intraoperative technique. 
The Case 
A 52-year-old male had spent 6 months on the waiting list for a deceased donor 
kidney transplant when he was admitted for a right sided medial opening wedge high 
tibial osteotomy for symptomatic medial compartment osteoarthritis in June 2016.  
His primary renal diagnosis was focal segmental global sclerosis secondary to 
chronic IgA nephropathy which had presented as acute nephritic syndrome seven 
years prior. This had progressed in the context of heavy proteinuria until he had 
commenced haemodialysis two years prior to admission.  
 
His dialysis history was uneventful. He dialysed through a tunnelled central vascular 
catheter three times a week. His sessions were well tolerated, he had never had any 
dialysis associated infections and his treatment adequacy and biochemical control 
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were excellent. He had never required any blood transfusions, his haemoglobin 
being well maintained instead by twice weekly subcutaneous erythropoietin beta.  
The patient had undergone an identical operation in his opposite knee two years 
prior to this procedure to good effect and he continued working in an active job in the 
catering industry.  
 
His HLA antibody profile was established during his evaluation prior to placement 
onto the transplant waiting list. Importantly, prior to his orthopaedic surgery he had 
no detectable anti-HLA antibodies. 
 
His surgical course was uncomplicated. Intraoperative blood loss was minimal and 
no blood products were administed at any point. In order to improve stability and 
promote healing at the osteotomy site the operating team elected to deploy two 
wedges of femoral head allograft bone graft in addition to the osteotomy plate. The 
estimated volume of bone graft used was 2cm3.This was fresh frozen bone supplied 
by the national bone bank. Our local protocol involves donor screening for blood 
borne virus testing and for blood group (allowing issue of RhD negative bone to 
recipient females of child bearing potential who are RhD negative). A small section of 
bone is removed for culture and the bone is then immediately stored fresh frozen at -
80°C (-112 °F) for up to 3 years. Bone is supplied unwashed to theatre, where surgical 
preference dictates whether bone is washed. The bone used in this case was not 
washed. 
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He contined to attend his haemodiaylsis post operatively and was discharged home 
following a brief in-patient stay. 
 
Five weeks following his surgery, a routine antibody profile update was performed. 
His antibody profile was found to be substantially changed compared to his previous 
negative samples, with the presence of HLA class II antibodies (figure 1). Single 
antigen bead array analysis (One Lambda and Immucor) using the Luminex platform 
showed the presence of HLA-DR, DQ and DP specificities, at levels that would be 
likely to give a positive flow cytometry crossmatch and therefore according to local 
procedures required listing as unacceptable antigens for organ allocation. The 
calculated reaction frequency (cRF) level was 99%.  
 
DNA from the bone graft donor was extracted from a residual plasma sample and 
HLA typed using Luminex SSO (One Lambda). The HLA types of the patient and the 
bone donor showed a 1,1,2 mismatch for HLA-A,B and DR. Allele level donor and 
patient HLA types were imputed from the SSO data  and with the patient HLA 
antibody data were used in an epitope analysis (Matchmaker) to assess the 
likelihood of the bone donor being the cause of patient sensitisation (Figure 1). The 
results showed the presence of antibodies directed against mismatched donor HLA 
epitopes. Repeat testing six months following the procedure demonstrated 
persistance of the class II reactivity, although the median florescent intensity values 
were noted to have decreased. 
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Discussion 
Bone Grafting 
Bone grafting is a common orthopaedic procedure performed to augment post-
operative bone regeneration. An autologous bone graft remains the gold standard 
and common harvesting sites include the iliac crest and intramedullary canal of long 
bones.(7,8) However, it is well recognised that harvesting of autologous bone graft is 
associated with an increase in postoperative pain and donor site morbidity. 
Alternatives to autologous graft include allograft bone graft, allograft demineralized 
bone matrix and synthetic material (e.g. tricalcium phosphate or hydroxyapatite). 
Bone allografts are kept in a local hospital banks or national bone banks. The 
primary source of bone allograft is femoral heads, donated by patients following hip 
arthroplasty. Bone grafts may also be donated by deceased donors.(9) 
The method of processing depends on the specific bank but can vary from the graft 
being used fresh, freeze dried or frozen. Many are transplanted without further 
processing, but protocols do exist for allograft “washing”. These protocols may 
include various degrees of heat treatment, the use of ethylene oxide sterilisation and 
gamma radiation. Over 95% of leukocytes and plasma components, as measured by 
elastase and soluble protein, can be removed in such a manner.(10) These protocols 
are primarily driven by infectious concerns rather than any immunological 
considerations.(10,11) Despite this, animal models suggest that frozen and freeze 
dried bone transplants are less immunogenic than fresh bone and have more 
successful engraftment.(12) 
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During the normal healing process of a bone allograft, revascularization and 
osteoclastic activity are thought to continuously replace the cells of the allograft with 
host bone. This cellular invasion and neovascularisation does have some similarities 
to elements of transplant rejection, leading some authors to question the applicability 
of traditional concepts of rejection to bone grafts.(13) 
Previous clinical experience 
Allograft bone procedures are performed without any HLA matching or 
immunosuppression protocols. This is considered clinically unnecessary given that 
clinical rejection is extremely rare, although it has been reported to occur.(14) 
Despite early evidence to the contrary, it has been noted that the overall anti HLA 
antibody profile of patients can be altered following bone graft donation, although 
there has been a paucity of data specifically measuring anti-HLA antibodies outside 
of massive osteochondral transplants.(15,16) 
Evidence that alloimmunization may occur comes from a multicentre prospective 
study of patients receiving cortex-replacing, massive structural bone allografts. It was 
noted that donor-specific HLA sensitization occurred in 57% of the patients but 
subsequently had no demonstrable effect on bone graft incorporation or union.(17)  
A second prospective study population demonstrated massive bone transplantation 
operations were associated with donor-specific HLA sensitization in 53% of 
previously nonsensitized patients.(18) Both studies pertained to bone transplant on a 
much larger scale than our case - massive osteochondral grafts due to trauma or 
malignancy, with consequently larger antigenic loads, more varied antigen 
exposures, and were potentially confounded by coexistent bloods transfusions. Such 
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observational studies do serve as a proof of concept that bone grafts can generate a 
clinically significant response, but protein characterization of the immunoreactive 
proteins revealed that the majority of antigenic targets were fragments of various 
collagen molecules.(19) 
 
Specific cases relating to HLA sensitisation that may inform our practice within 
clinical transplant medicine are very limited. Following a total knee arthroplasty to 
treat osteosarcoma and composite bone allograft prosthesis a potential kidney 
transplant recipient’s PRA rose from 28% to a peak of 70%.(20) A second report of a 
patient developing DSA, also following osteosarcoma resection and tibial 
reconstruction with allogenic bone graft has been reported. While this patient had a 
concomitant blood transfusion, it is possible that the large quantity of bone used was 
a factor in inducing allosensitization.(6) 
Our case represents the first description of allosensitization following a simple bone 
graft with a very small volume of donor bone used and adds to a small but significant 
body of evidence surrounding the immunology of bone grafts. This is an interesting 
observation as it is expected that there would be few HLA class II positive cells in the 
graft. One potential source of HLA class II positive cells in a bone graft could include 
residual bone marrow which could include dendritic cells, macrophages and B-cells. 
Furthermore, recent evidence has demonstrated that crosstalk between the immune 
system and cells of bone lineage is more common that previously recognised. 
Osteoblasts have been noted to express MHC class II surface proteins and act as 
antigen presenting cells.(21) Additionally data suggest a large proportion of 
osteocytes die following bone grafting, which may explain the why allosensitization 
via these cells is far less common than one might expect.(22) 
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Conclusions 
When planning orthopaedic surgery for potential transplant recipients, clinicians 
should be aware of the risk of allosensitization where bone grafts are used. These 
may not be immediately recognised as a potential source of antigenic exposure, but 
the lack of HLA matching and immunosuppression when they are used can prove to 
be a source of sensitisation. Furthermore, decisions surrounding the use of donor 
bone may not be entirely predictable as individual surgical teams may need to 
unexpectedly consider bone grafting intraoperatively. 
Pragmatically, consideration should be given to washing bone to reduce the 
antigenic load or to the use of osteoconductive alternatives to bone grafts if 
appropriate. This would include synthetic materials such as hydroxyapatite and 
calcium phosphate cements. These materials are useful in providing structural 
support after osteotomy and other orthopaedic procedures but have no risk of 
sensitization as there is no antigenic component. Other alternatives include 
osteoinductive materials of which demineralized bone matrix has been the most 
commonly used. This is a particulate powder in a carrier putty composed of 93% 
collagen, 5% soluble osteoinductive proteins and 2% residual mineralized 
matrix.(23,24)  Importantly, this still has potential for alloimmunization given the 
potential antigenic load of protein and bone matrix.  
Finally, increasingly diverse tissues are now transplanted routinely, including hands, 
vessels, nerves, skin, cartilage, tendons and muscle. As with bone, these 
procedures should all be considered as potential sources of alloimmunization in 
patients awaiting solid organ transplant, and their exposure to such sources should 
be minimised where practical and possible. 
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Figure Legend 
Figure 1: Patient and donor HLA types were determined by Luminex SSO typing and 
inputted into HLAMatchmaker allowing determination of mismatched class II 
epitopes. (HLA class I epitope mismatches were not determined as patient remained 
class I antibody negative). Mismatched alleles to which antibody was generated are 
highlighted in boxes. Analysis of reactive serum post orthopaedic surgery 
demonstrates possible reactivity with 6 of the mismatched HLA class II epitopes 
across HLA-DRB1, DQB1 and DPB1 alleles. Reactivity is shown in descending order 
of MFI, strongest reactivity directed towards DQ6 alleles with epitope 52PQ2 
demonstrating the strongest levels in terms of MFI (52PQ2 actually indicates two 
separate configurations 52P53Q and 84E85V in opposite locations on the top of the 
DQB molecule). Interestingly reactivity appears to have been generated towards all 
HLA-DR, DQ and DP loci. Antibody reactive epitopes listed as confirmed in the HLA 
epitope registry are shown in bold in the table; the other antibody reactive epitopes 
are listed as provisional in the database.(25) 
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